Riskpilot← Back to searchSign inGet full accessSeqCure Immunology AB
ABActiveOrg 5590947031Nanna Svartz Väg 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 20161 employees
Revenue 2025
SEK -1
EBITDA margin
-149080900.0%
+272% vs 2024
Equity ratio
69.3%
Financial strength
Net profit 2025
SEK 1,5M
+271% vs 2024
| Revenue | SEK -1 | — |
| EBITDA | SEK 1,5M | +272% |
| Net profit | SEK 1,5M | +271% |
| Total assets | SEK 2,7M | +1015% |
| Equity | SEK 1,8M | +1188% |
| Employees | 1 | — |
Legal name
SeqCure Immunology AB
Org number
5590947031
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 december 2016
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva service och konsultverksamhet inom bioteknologi, hälso och sjukvård samt försäljning av system för cellterapi och därmed förenlig verksamhet.
Address
Nanna Svartz Väg 2
Email
ludvig@seqcureimmunology.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 20 | 0 | 0 | 0 | −0 |
| Staff expenses | — | — | −73 | −652 | −1 122 |
| EBITDA | −519 | −303 | −726 | −869 | 1 491 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −519 | −303 | −726 | −869 | 1 491 |
| Net financials | −10 | −7 | −5 | −1 | −0 |
| Profit before tax | −529 | −310 | −731 | −870 | 1 491 |
| Tax | −0 | — | — | — | — |
| Net profit | −529 | −310 | −731 | −870 | 1 491 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 104 | 66 | 978 | 238 | 2 652 |
| Equity | −572 | −882 | 837 | 143 | 1 838 |
| Long-term debt | 579 | 829 | 35 | 0 | 495 |
| Short-term debt | 98 | 119 | 105 | 95 | 319 |
| Total debt | 677 | 948 | 141 | 95 | 814 |
EBITDA margin
149080900.0%
This company
15.8%
Market median
+943549900% vs market
20212025
Equity ratio
69.3%
This company
38.2%
Market median
+81% vs market
20212025
Return on equity
81.1%
This company
18.4%
Market median
+341% vs market
20212025
Net profit margin
149068400.0%
This company
8.1%
Market median
+1840350517% vs market
20212025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HV Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SeqCure Immunology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Vidar Wendel-Hansen | Chief Executive Officer | 0 companies |
| Emma Kristina Lindh | Deputy Board Member | 0 companies |
| Robert Per-Anders Wallin | Chairman | 0 companies |
| Bernt Ludvig Linton | Board of Directors | 0 companies |